Vaxcyte, Inc. $PCVX Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 3.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 587,054 shares of the company’s stock after selling 18,213 shares during the quarter. American Century Companies Inc. owned 0.46% of Vaxcyte worth $22,167,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of PCVX. Parallel Advisors LLC boosted its stake in shares of Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company’s stock valued at $61,000 after buying an additional 1,071 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Vaxcyte by 376.4% during the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after purchasing an additional 1,306 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of Vaxcyte by 10.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company’s stock worth $112,000 after purchasing an additional 293 shares in the last quarter. J.Safra Asset Management Corp boosted its position in shares of Vaxcyte by 65.8% during the 1st quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company’s stock worth $119,000 after purchasing an additional 1,254 shares in the last quarter. Finally, GF Fund Management CO. LTD. boosted its position in shares of Vaxcyte by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company’s stock worth $121,000 after purchasing an additional 575 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Cowen restated a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the stock. According to data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and a consensus target price of $136.50.

Vaxcyte Price Performance

NASDAQ PCVX opened at $32.29 on Friday. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06. The company has a market capitalization of $4.19 billion, a P/E ratio of -7.86 and a beta of 1.21. The business has a 50 day moving average price of $33.64 and a 200 day moving average price of $44.41.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter in the previous year, the firm earned ($1.10) earnings per share. On average, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.